Related Experiment Video
Updated: Aug 30, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Using risk-adjustment models to identify high-cost risks
Richard T Meenan1, Michael J Goodman, Paul A Fishman
1Center for Health Research, Northwest and Hawaii, Kaiser Permanente Northwest, Portland, Oregon 97227, USA. richard.meenan@kpchr.org
Background:
We examine the ability of various publicly available risk models to identify high-cost individuals and enrollee groups using multi-HMO administrative data.
Methods:
Five risk-adjustment models (the Global Risk-Adjustment Model [GRAM], Diagnostic Cost Groups [DCGs], Adjusted Clinical Groups [ACGs], RxRisk, and Prior-expense) were estimated on a multi-HMO administrative data set of 1.5 million individual-level observations for 1995-1996. Models produced distributions of individual-level annual expense forecasts for comparison to actual values. Prespecified "high-cost" thresholds were set within each distribution. The area under the receiver operating characteristic curve (AUC) for "high-cost" prevalences of 1% and 0.5% was calculated, as was the proportion of "high-cost" dollars correctly identified. Results are based on a separate 106,000-observation validation dataset.
Main Results:
For "high-cost" prevalence targets of 1% and 0.5%, ACGs, DCGs, GRAM, and Prior-expense are very comparable in overall discrimination (AUCs, 0.83-0.86). Given a 0.5% prevalence target and a 0.5% prediction threshold, DCGs, GRAM, and Prior-expense captured $963,000 (approximately 3%) more "high-cost" sample dollars than other models. DCGs captured the most "high-cost" dollars among enrollees with asthma, diabetes, and depression; predictive performance among demographic groups (Medicaid members, members over 64, and children under 13) varied across models.
Conclusions:
Risk models can efficiently identify enrollees who are likely to generate future high costs and who could benefit from case management. The dollar value of improved prediction performance of the most accurate risk models should be meaningful to decision-makers and encourage their broader use for identifying high costs.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Hazard Rate
Relative Risk
Hazard Ratio
For example, in a clinical trial evaluating a...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions